The optimization of recombinant antibody production from Chinese hamster ovary (CHO) cells presents a paramount challenge with the biopharmaceutical industry. Various strategies are employed maximize antibody titer, including process parameter optimization, cell line development, and implementation of perfusion technologies. Fine-tuning growth pa